ATE232536T1 - N-(2-(5-benzyloxycarbonyl-amino-6-oxo-2-(4- - Google Patents

N-(2-(5-benzyloxycarbonyl-amino-6-oxo-2-(4-

Info

Publication number
ATE232536T1
ATE232536T1 AT98958672T AT98958672T ATE232536T1 AT E232536 T1 ATE232536 T1 AT E232536T1 AT 98958672 T AT98958672 T AT 98958672T AT 98958672 T AT98958672 T AT 98958672T AT E232536 T1 ATE232536 T1 AT E232536T1
Authority
AT
Austria
Prior art keywords
compound
benzyloxycarbonyl
oxo
amino
disease
Prior art date
Application number
AT98958672T
Other languages
German (de)
English (en)
Inventor
Gerald Paul Schielke
Aurash Shahripour
Original Assignee
Warner Lambert Co
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co, Abbott Gmbh & Co Kg filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE232536T1 publication Critical patent/ATE232536T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT98958672T 1998-01-20 1998-11-20 N-(2-(5-benzyloxycarbonyl-amino-6-oxo-2-(4- ATE232536T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7191898P 1998-01-20 1998-01-20
PCT/US1998/024848 WO1999036426A1 (en) 1998-01-20 1998-11-20 N-[2-(5-BENZYLOXYCARBONYL-AMINO-6-OXO-2-(4-FLUOROPHENYL)-1,6-DIHYDRO-1-PYRIMIDINYL)ACETO- XYL]-L-ASPARTIC ACID ALDEHYDE AS AN IN VIVO INHIBITOR OF INTERLEUKIN-1β CONVERTING ENZYME (ICE)

Publications (1)

Publication Number Publication Date
ATE232536T1 true ATE232536T1 (de) 2003-02-15

Family

ID=22104428

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98958672T ATE232536T1 (de) 1998-01-20 1998-11-20 N-(2-(5-benzyloxycarbonyl-amino-6-oxo-2-(4-

Country Status (11)

Country Link
EP (1) EP1049703B1 (https=)
JP (1) JP2002509153A (https=)
AT (1) ATE232536T1 (https=)
AU (1) AU1466399A (https=)
CA (1) CA2309546A1 (https=)
DE (1) DE69811404T2 (https=)
DK (1) DK1049703T3 (https=)
ES (1) ES2193589T3 (https=)
PT (1) PT1049703E (https=)
WO (1) WO1999036426A1 (https=)
ZA (1) ZA99369B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867217B1 (en) 1999-05-19 2005-03-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6653316B1 (en) 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6716838B1 (en) 1999-05-19 2004-04-06 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
US7015230B1 (en) 1999-05-19 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6750342B1 (en) 1999-05-19 2004-06-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6664255B1 (en) 1999-05-19 2003-12-16 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
WO2001068605A1 (en) 2000-03-13 2001-09-20 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
ATE289299T1 (de) 2000-04-05 2005-03-15 Pharmacia Corp Polyzyclisch aryl und heteroaryl substituierte 4- pyronen verwendbar als selektive hemmung von dem koagulationsprozess
EP1268428A2 (en) 2000-04-05 2003-01-02 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade
JP2004501077A (ja) 2000-04-17 2004-01-15 ファルマシア・コーポレーション 凝固カスケードの選択的阻害に有用な多環式アリールおよびヘテロアリール置換1,4−キノン
AU2001222501A1 (en) * 2000-05-18 2001-11-26 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
JP2004504302A (ja) 2000-07-18 2004-02-12 ニューロジェン・コーポレーション 5−置換2−アリール−4−ピリミジノン
US7119094B1 (en) 2000-11-20 2006-10-10 Warner-Lambert Company Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade
US7015223B1 (en) 2000-11-20 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade
EP1351686A2 (en) 2000-11-20 2003-10-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
PH12012502440A1 (en) 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl
MXPA04003163A (es) 2001-10-03 2004-07-08 Pharmacia Corp Compuestos heterociclicos de 6 elementos utiles para inhibicion selectiva de la casdada de coagulacion.
WO2003093242A2 (en) 2001-10-03 2003-11-13 Pharmacia Corporation Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
CA2824167C (en) 2002-09-06 2018-09-25 Amgen Inc. Therapeutic human anti-il-1r1 monoclonal antibody
SG150547A1 (en) 2004-03-12 2009-03-30 Vertex Pharma Processes and intermediates
MXPA06013256A (es) 2004-05-15 2007-02-08 Vertex Pharma Tratamiento de crisis convulsivas utilizando inhibidores ice.
CA2567080A1 (en) 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Ice inhibitors for the treatment of autoinflammatory diseases
KR20080038369A (ko) 2005-07-28 2008-05-06 버텍스 파마슈티칼스 인코포레이티드 카스파제 억제제 프로드럭
US9116157B2 (en) 2010-11-05 2015-08-25 Brandeis University Ice-cleaved alpha-synuclein as a biomarker
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
EP4526469A1 (en) 2022-05-16 2025-03-26 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441960A (en) * 1992-04-16 1995-08-15 Zeneca Limited 1-pyrimidinylacetamide human leukocyte elastate inhibitors
CN1118458C (zh) * 1994-03-31 2003-08-20 弗特克斯药品有限公司 作为白细胞介素抑制剂的嘧啶基衍生物

Also Published As

Publication number Publication date
DK1049703T3 (da) 2003-06-02
AU1466399A (en) 1999-08-02
PT1049703E (pt) 2003-06-30
DE69811404D1 (de) 2003-03-20
JP2002509153A (ja) 2002-03-26
ES2193589T3 (es) 2003-11-01
WO1999036426A1 (en) 1999-07-22
EP1049703A1 (en) 2000-11-08
CA2309546A1 (en) 1999-07-22
EP1049703B1 (en) 2003-02-12
DE69811404T2 (de) 2003-12-04
ZA99369B (en) 1999-07-20

Similar Documents

Publication Publication Date Title
ATE232536T1 (de) N-(2-(5-benzyloxycarbonyl-amino-6-oxo-2-(4-
NO991674L (no) Interleukin-1<Beta>omdannelsesenzym-inhibitor-sulfonamider
CA2338220A1 (en) Substituted imidazoles having cytokine inhibitory activity
EP1034164A4 (en) BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS
EA199800923A1 (ru) Новые 2,3-двузамещенные 4(3н)-хиназолины
DE69615682D1 (de) N-(1-alkyl-5-phenyl-2,3,4,5-tetrahydro-1-h-benzo[b][1,5]-diazepin-3-yl)-acetamide
DK0765320T3 (da) Benzimidazolonderivater med central dopaminerg aktivitet
AP2000001992A0 (en) Succinamide inhibitors of inteleukin-1B converting enzyme.
DE69811360D1 (de) Diazepinoindolone als phophodiesterase 4 inhibitoren
EA200000741A1 (ru) Новые производные дигидроксигексановой кислоты
EA200000204A1 (ru) Производные пирролопирролона в качестве ингибиторов эластазы нейтрофилов
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
BR9713314A (pt) Inibidores da enzima de conversão interleucina-1beta de ácido aspártico substituìdo com sulfonamida
EP0637961A4 (en) METHOD FOR TREATING INFLAMMABLE INTESTINAL DISEASES WITH LEUKOTRIA SYNTHESIS INHIBITORS.
DE60133385D1 (de) (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen
BR9916189A (pt) Derivados de amida arilpiperidina e aril-1,2,5,6-tetraidropiridina tendo atividade receptora 5ht1a
EP0785989A4 (en) MICROBIAL SYNTHESIS OF INHIBITORS OF THE HIV PROTEASE
EP1305008A4 (en) Improved forms of pharmaceutical ingredients and method for their preparation
FR2800391B1 (fr) Procede de renovation d'etuves

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1049703

Country of ref document: EP

REN Ceased due to non-payment of the annual fee